GO
Loading...

Bristol-Myers Squibb Co

More

  • Your first trade for Tuesday Monday, 12 Jan 2015 | 6:23 PM ET

    The "Fast Money" traders give their final trades of the day.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...

  • *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-week decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • Early movers: TIF, DLTR, CZR, MS, GM & more Monday, 12 Jan 2015 | 7:58 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures climb after two-week drop Monday, 12 Jan 2015 | 7:35 AM ET

    *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • Jan 11- Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint. The company said the data demonstrates superior overall survival in patients receiving Opdivo...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of an anticoagulant drug in a late-stage study, sending the company's shares up 11 percent in premarket trading. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto, developed by...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of Johnson& Johnson's blood thinner, Xarelto, in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto in healthy volunteers aged 50-75 years.

  • Cramer Remix: Party with these rock star stocks Thursday, 8 Jan 2015 | 7:15 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.

  • NEW YORK, Jan 7- Halozyme Therapeutics Inc believes it has a multibillion-dollar cancer drug on its hands. Halozyme discussed interim data from a Phase II study of PEGPH20 with analysts and investors in New York on Wednesday, demonstrating its likelihood of delaying a worsening of the deadly cancer. "All that matters is that the tumor has to have a high...

  • FDA approves 41 novel medicines in 2014 vs 27 in 2013. LONDON, Jan 1- U.S. drug approvals in 2014 hit their highest level in 18 years and recommendations in Europe also came at a rapid rate, driven by expensive new treatments for cancer and rare diseases. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines in...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • FDA approves Bristol-Myer's skin cancer drug Monday, 22 Dec 2014 | 2:32 PM ET

    Dec 22- The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's drug for an advanced form of skin cancer. The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. The FDA's approval comes well before its scheduled review date of March 30.

  • Cramer Remix: Here’s what the Fed did Wednesday, 17 Dec 2014 | 7:06 PM ET
    Jim Cramer on Mad Money.

    The market may have rallied, but "Mad Money" host Jim Cramer thinks that’s just the beginning of Yellen’s impact.